PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer

A multicenter, open‐label, noncomparative, randomized phase II study (PEPCOL) was conducted to evaluate the efficacy and safety of the irinotecan or PEP02 (MM‐398, nanoliposomal irinotecan) with leucovorin (LV)/5‐fluorouracil (5‐FU) combination as second‐line treatment in patients with metastatic co...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Chibaudel, Benoist, Maindrault‐Gœbel, Frédérique, Bachet, Jean‐Baptiste, Louvet, Christophe, Khalil, Ahmed, Dupuis, Olivier, Hammel, Pascal, Garcia, Marie‐Line, Bennamoun, Mostefa, Brusquant, David, Tournigand, Christophe, André, Thierry, Arbaud, Claire, Larsen, Annette K, Wang, Yi‐Wen, Yeh, C. Grace, Bonnetain, Franck, de Gramont, Aimery
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Cancer Biology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4831286/
https://ncbi.nlm.nih.gov/pubmed/26806397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.635
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados